Clinical trial
Study of Velcade and Thalidomide in Patients With Myelodysplasia
NCT00271804 · Massachusetts General Hospital, Other · Terminated
Key facts
| NCT number | NCT00271804 |
|---|---|
| Title | Study of Velcade and Thalidomide in Patients With Myelodysplasia |
| Official title | Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Brigham and Women's Hospital Beth Israel Deaconess Medical Center |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 28 |
| Start date | Jun 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Jan 4, 2006 |
| Last update posted | Mar 13, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: